Smith Drug Co. v. Actavis (Namenda), No. 15-7488 (S.D.N.Y.)
Smith Drug Co. v. Actavis (Namenda), No. 15-7488 (S.D.N.Y.), Faruqi & Faruqi representing a pharmaceutical wholesaler and a proposed class of direct purchasers of Actavis’ Namenda XR, alleging that Actavis Actavis engaged in an illegal product hop to move the market from Namenda to Namenda XR in order to thwart competition from generic Namenda.(settled for $750 million)
If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.
685 Third Avenue 26th Floor
10017 New York, New York
Joseph T. Lukensjlukens@faruqilaw.comPhone (215) 277-5770Fax (215) 277-5771
Peter Kohnpkohn@faruqilaw.comPhone (215) 277-5770Fax (215) 277-5771
Our offices are nationwide. If you have any questions about a case or our firm, please contact us.
685 Third Avenue 26th Floor New York, New York10017 (212) 983-9330 (877) 247-4292 (212) 983-9331
1901 Avenue of the Stars Suite 1060 Los Angeles, California90067 (424) 256-2884 (424) 256-2885
3565 Piedmont Road NE Building Four, Suite 380 Atlanta, Georgia30305 (404) 847-0617 (404) 506-9534